We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $459M
1-Year Est. Return 93.97%
This Fund
S&P 500
This Quarter Est. Return
+33.31%
1 Year Est. Return
+93.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$459M
AUM Growth
+$347M
Cap. Flow
+$245M
Cap. Flow %
53.32%
Top 10 Hldgs %
63.7%
Holding
167
New
86
Increased
23
Reduced
20
Closed
38

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$30.6M
2
GS icon
Goldman Sachs
GS
+$30.2M
3
XOM icon
ExxonMobil
XOM
+$26.8M
4
GPN icon
Global Payments
GPN
+$26.4M
5
NVDA icon
NVIDIA
NVDA
+$25.8M

Top Sells

Rank Stock Value
1
ASX icon
ASE Group
ASX
+$3.89M
2
ASND icon
Ascendis Pharma A/S
ASND
+$2.71M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$2.01M
4
PFE icon
Pfizer
PFE
+$2M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.93M

Sector Composition

Rank Sector Weight
1 Miscellaneous 28.72%
2 Healthcare 18.58%
3 Financials 14.08%
4 Industrials 12.67%
5 Technology 12.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
26
Humana
HUM
$48.2B
$3.11M 0.68%
+7,839
New +$2.23M
LLY icon
27
Eli Lilly
LLY
$1.02T
$3.06M 0.67%
2,548
+2,106
+476% +$2.15M
RVTY icon
28
Revvity
RVTY
$14.5B
$3.04M 0.66%
+27,316
New +$2.63M
PTCT icon
29
PTC Therapeutics
PTCT
$5.78B
$3.01M 0.66%
36,873
-2,828
-7% -$204K
ABBV icon
30
AbbVie
ABBV
$453B
$3M 0.65%
+11,928
New +$2.57M
CHE icon
31
Chemed
CHE
$6.79B
$2.96M 0.65%
+6,365
New +$2.68M
SOXX icon
32
iShares Semiconductor ETF
SOXX
$42.8B
$2.94M 0.64%
+4,590
New +$2.33M
A icon
33
Agilent Technologies
A
$42.5B
$2.9M 0.63%
+21,826
New +$2.66M
NBIX icon
34
Neurocrine Biosciences
NBIX
$15.8B
$2.78M 0.61%
16,490
-5,066
-24% -$752K
TEVA icon
35
Teva Pharmaceuticals
TEVA
$42.4B
$2.78M 0.61%
81,993
+56,188
+218% +$1.87M
ALAB icon
36
Astera Labs
ALAB
$53.8B
$2.56M 0.56%
+5,293
New +$1.4M
COO icon
37
Cooper Companies
COO
$13.6B
$2.49M 0.54%
34,743
+28,847
+489% +$1.89M
TWST icon
38
Twist Bioscience
TWST
$8.21B
$2.09M 0.45%
20,287
+6,811
+51% +$443K
QCOM icon
39
Qualcomm
QCOM
$180B
$2.06M 0.45%
+11,141
New +$2.08M
ACHC icon
40
Acadia Healthcare
ACHC
$2.62B
$1.97M 0.43%
+66,843
New +$1.72M
DVA icon
41
DaVita
DVA
$11.7B
$1.79M 0.39%
+8,046
New +$1.46M
ALNY icon
42
Alnylam Pharmaceuticals
ALNY
$35.6B
$1.68M 0.37%
+5,588
New +$1.69M
CON
43
Concentra Group Holdings
CON
$4.4B
$1.57M 0.34%
+52,747
New +$1.31M
BMRN icon
44
BioMarin Pharmaceuticals
BMRN
$12.9B
$1.55M 0.34%
27,041
-21,678
-44% -$1.19M
BIIB icon
45
Biogen
BIIB
$32.6B
$1.48M 0.32%
6,838
+2,132
+45% +$408K
OSCR icon
46
Oscar Health
OSCR
$9.95B
$1.46M 0.32%
+51,105
New +$1.1M
LRCX icon
47
Lam Research
LRCX
$385B
$1.4M 0.3%
+3,230
New +$981K
XLV icon
48
State Street Health Care Select Sector SPDR ETF
XLV
$44.1B
$1.36M 0.3%
+8,600
New +$1.28M
AVTR icon
49
Avantor
AVTR
$10.1B
$1.3M 0.28%
+131,088
New +$1.13M
RMBS icon
50
Rambus
RMBS
$9.27B
$1.27M 0.28%
+9,559
New +$1.24M
1
2
3 4 5

Similar funds

VIM
VELA Investment Management New Albany, Ohio $459M AUM 18.61% 1-Year Est. Return
AM
Atwater Malick Lancaster, Pennsylvania $459M AUM 37.25% 1-Year Est. Return
SSC
Syverson Strege & Co West Des Moines, Iowa $459M AUM 27.74% 1-Year Est. Return
RFN
RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return
PWS
Peterson Wealth Services South Ogden, Utah $459M AUM 42.99% 1-Year Est. Return
GCM
G2 Capital Management Columbus, Ohio $459M AUM 18.56% 1-Year Est. Return
CIM
Coleford Investment Management Toronto, Ontario, Canada $459M AUM 23.79% 1-Year Est. Return
RAG
RIA Advisory Group Des Moines, Iowa $460M AUM 29% 1-Year Est. Return

Arrowpoint Investment Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Arrowpoint Investment Partners held 167 positions worth $459M, up 308% from $113M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Arrowpoint Investment Partners deployed $245M of net new capital in Q2 2026, opening 86 new positions and adding to 23 existing holdings. Its largest new stake was Citigroup: 235,033 shares worth $32.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $2.01M trimmed.

  • Arrowpoint Investment Partners's largest Q2 2026 buy was Citigroup: 235,033 shares worth $32.9M.
  • Arrowpoint Investment Partners added most to Insmed in Q2 2026, an estimated $2.8M increase.
  • Arrowpoint Investment Partners's biggest Q2 2026 reduction was Ionis Pharmaceuticals, cutting an estimated $2.01M.
  • Arrowpoint Investment Partners fully exited ASE Group in Q2 2026, selling an estimated $3.89M.
  • Arrowpoint Investment Partners's ten largest holdings make up 64% of its $459M portfolio in Q2 2026.
  • Arrowpoint Investment Partners opened 86 new positions and closed 38 in Q2 2026.
  • Arrowpoint Investment Partners's portfolio value rose 308% quarter-over-quarter to $459M.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.